Pulmonary hypertension in left heart disease: A review

被引:6
作者
Corte, Tamera J. [1 ,2 ]
McDonagh, Theresa A. [2 ]
Wort, Stephen J. [2 ]
机构
[1] Royal Prince Alfred Hosp, Dept Resp Med, Sydney, NSW 2050, Australia
[2] Royal Brompton Hosp, Natl Heart & Lung Inst, Dept Pulm Hypertens, London SW3 6LY, England
关键词
Diagnosis; Heart failure; Diastolic heart failure; Prognosis; Pulmonary hypertension; Treatment; INHALED NITRIC-OXIDE; ENDOTHELIN-RECEPTOR ANTAGONIST; CLINICAL-TRIALS; ARTERIAL-HYPERTENSION; VASCULAR-RESISTANCE; PLASMA ENDOTHELIN; OXYGEN-THERAPY; FAILURE; SILDENAFIL; TRANSPLANTATION;
D O I
10.1016/j.ijcard.2011.06.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pulmonary hypertension (PH) occurs commonly in patients with left heart disease, and is associated with increased morbidity and mortality. The pathophysiologic mechanisms of PH in left heart disease are complex, and are thought to be a composite of both passive and active components. PH that is disproportionate to the underlying left heart disease may be attributable to reactive pulmonary vascular remodelling. Management of these patients is focused upon treatment of the underlying left heart disease and its associated comorbidities. There is no supporting evidence for the routine use of specific PH therapies in these patients at present. However, there is some suggestion that PDE-5 inhibitors may be useful, but their safety and efficacy needs to be formally evaluated in controlled trials before further recommendations are made. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:253 / 258
页数:6
相关论文
共 63 条
[1]  
Abrahams W, 2001, CLIN CARDIOL, V24, P481
[2]   PULMONARY-HYPERTENSION PREDICTS MORTALITY AND MORBIDITY IN PATIENTS WITH DILATED CARDIOMYOPATHY [J].
ABRAMSON, SV ;
BURKE, JF ;
KELLY, JJ ;
KITCHEN, JG ;
DOUGHERTY, MJ ;
YIH, DF ;
MCGEEHIN, FC ;
SHUCK, JW ;
PHIAMBOLIS, TP .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (11) :888-895
[3]  
ADDONIZIO LJ, 1987, CIRCULATION, V76, P52
[4]   Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH):: randomised, double-blind, placebo-controlled trial [J].
Anand, I ;
McMurray, J ;
Cohn, JN ;
Konstam, MA ;
Notter, T ;
Quitzau, K ;
Ruschitzka, F ;
Lüscher, TF .
LANCET, 2004, 364 (9431) :347-354
[5]   NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension [J].
Blyth, K. G. ;
Groenning, B. A. ;
Mark, P. B. ;
Martin, T. N. ;
Foster, J. E. ;
Steedman, T. ;
Morton, J. J. ;
Dargie, H. J. ;
Peacock, A. J. .
EUROPEAN RESPIRATORY JOURNAL, 2007, 29 (04) :737-744
[6]   Acute Hemodynamic Effects of Intravenous Sildenafil Citrate in Congestive Heart Failure: Comparison of Phosphodiesterase Type-3 and-5 Inhibition [J].
Botha, Phil ;
Parry, Gareth ;
Dark, John H. ;
MacGowan, Guy A. .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2009, 28 (07) :676-682
[7]   A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST) [J].
Califf, RM ;
Adams, KF ;
McKenna, WJ ;
Gheorghiade, M ;
Uretsky, BF ;
McNulty, SE ;
Darius, H ;
Schulman, K ;
Zannad, F ;
HandbergThurmond, E ;
Harrell, FE ;
Wheeler, W ;
SolerSoler, J ;
Swedberg, K .
AMERICAN HEART JOURNAL, 1997, 134 (01) :44-54
[8]   PLASMA ENDOTHELIN CORRELATES WITH THE EXTENT OF PULMONARY-HYPERTENSION IN PATIENTS WITH CHRONIC CONGESTIVE-HEART-FAILURE [J].
CODY, RJ ;
HAAS, GJ ;
BINKLEY, PF ;
CAPERS, Q ;
KELLEY, R .
CIRCULATION, 1992, 85 (02) :504-509
[9]   SELECTION AND TREATMENT OF CANDIDATES FOR HEART-TRANSPLANTATION - A STATEMENT FOR HEALTH-PROFESSIONALS FROM THE COMMITTEE ON HEART-FAILURE AND CARDIAC TRANSPLANTATION OF THE COUNCIL ON CLINICAL CARDIOLOGY, AMERICAN-HEART-ASSOCIATION [J].
COSTANZO, MR ;
AUGUSTINE, S ;
BOURGE, R ;
BRISTOW, M ;
OCONNELL, JB ;
DRISCOLL, D ;
ROSE, E .
CIRCULATION, 1995, 92 (12) :3593-3612
[10]   INFLUENCE OF PREOPERATIVE PULMONARY-ARTERY PRESSURE ON MORTALITY AFTER HEART-TRANSPLANTATION - TESTING OF POTENTIAL REVERSIBILITY OF PULMONARY-HYPERTENSION WITH NITROPRUSSIDE IS USEFUL IN DEFINING A HIGH-RISK GROUP [J].
COSTARDJACKLE, A ;
FOWLER, MB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 19 (01) :48-54